Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Icecure Medical ( (ICCM) ).
On May 11, 2026, IceCure Medical Ltd. convened a Special General Meeting of Shareholders in Caesarea, Israel, which was initially adjourned at 5:00 p.m. local time due to lack of quorum but successfully reconvened at 6:30 p.m. with sufficient shareholder participation. At the adjourned meeting, shareholders approved the single agenda item set out in the company’s previously distributed proxy materials, signaling alignment with management’s proposed corporate actions.
The outcome of the May 11, 2026 meeting enables IceCure to proceed with the approved measure without delay, reinforcing corporate governance processes and shareholder engagement. The Form 6-K filed in connection with the meeting is being incorporated by reference into IceCure’s existing U.S. registration statements, ensuring the updated corporate information is reflected in its capital markets documentation and maintaining regulatory compliance for securities offerings and employee equity plans.
The most recent analyst rating on (ICCM) stock is a Buy with a $1.00 price target. To see the full list of analyst forecasts on Icecure Medical stock, see the ICCM Stock Forecast page.
Spark’s Take on ICCM Stock
According to Spark, TipRanks’ AI Analyst, ICCM is a Neutral.
ICCM scores low overall primarily due to weak financial performance (large losses and significant cash burn despite modest revenue) and bearish technicals (below major moving averages with negative MACD). The latest earnings call adds meaningful upside from regulatory validation and stated commercial acceleration plans, but near-term execution and reimbursement timing risks keep the overall score constrained.
To see Spark’s full report on ICCM stock, click here.
More about Icecure Medical
IceCure Medical Ltd. is an Israel-based medical device company focused on minimally invasive cryoablation therapies, primarily targeting oncology indications. The company operates as a foreign private issuer listed in the U.S. capital markets, using shelf and employee equity registration statements to support its financing and incentive activities.
Average Trading Volume: 550,475
Technical Sentiment Signal: Sell
Current Market Cap: $16.49M
See more data about ICCM stock on TipRanks’ Stock Analysis page.